

Northern (NHS) Treatment Advisory Group

Current Work plan

Drug	Details	Provisional Meeting Date
Lurasidone in Bipolar Depression	Unlicensed indication	TBC
Inhaled levodopa for Parkinson's disease – not in in NICE workplan	New formulation as alternative to apomorphine. Not in NICE timetable.	On hold awaiting launch in UK of product.
Sublingual apomorphine for Parkinson's disease	New oral formulation. License expected 2023 Not in in NICE timetable.	TBC – depends on licensing/launch date
Intranasal adrenaline for anaphylaxis	Not in in NICE timetable.	TBC – depends on licensing/launch date
Osteoporosis guidelines	To develop regional guideline around latest NOGG guideline	TBC
National Shared Care Guideline templates including NENC DMARD share care guidelines	To consider regional adoption via a regional working group which will report back to NTAG.	Dronedarone and Sativex to May 2023 meeting
Olugo® pre-filled syringe of glucagon for hypoglycaemia	New formulation as alternative to GlucaGen® Not in NICE timetable.	To seek views of NENC diabetes network ahead of May 2023 meeting
Regional menopause guideline	To develop approved Tyne & Wear guideline as regional guideline	May 2023
IQuro device	To consider a regional formulary position based on NICE evidence reviews.	May 2023
Formulary applications <ul style="list-style-type: none"> • Ovamex® • Otinova® ear spray • 	To consider this new formulary applications.	May 2023

Potential Topics for re-review

Subcutaneous infliximab	To review this recommendation when ICS commissioning structures are more established and there is clarity on the ICS funding arrangements for high cost drugs.
-------------------------	--

NTAG
March 2022